NXEN OTC
Nexien BioPharma, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: -99.2%
3Y: -99.8%
5Y: -99.9%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000099999997-0.012
Volume115,000
Avg Volume332
Beta-0.88
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORichard S. Greenberg
Employees10
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2017-11-29
Websitenexienbiopharma.com
4340 East Kentucky Avenue
Glendale, CO 80246
US
Glendale, CO 80246
US
303 495 7583
About Nexien BioPharma, Inc.
Nexien BioPharma, Inc., a pharmaceutical firm headquartered in Glendale, Colorado, concentrates its efforts on the research, advancement, and market introduction of cannabinoid-derived medications. The company utilizes both pre-clinical and clinical development paths to address a variety of diseases, medical conditions, and disorders. It adopted its current name in September 2018, having previously operated as Intiva BioPharma Inc.
.jpg)
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Greenberg Richard S | A-Award | 1,000,000 | — | 2024-05-23 |
| Wasoff Evan L | A-Award | 2,000,000 | — | 2024-05-23 |
| Greenberg Richard S | A-Award | 250,000 | — | 2023-10-31 |
| Wasoff Evan L | A-Award | 250,000 | — | 2023-10-31 |
| Goldfarb Robert I | A-Award | 250,000 | — | 2023-07-25 |